Literature DB >> 23047173

Update on ocular tuberculosis.

Steven Yeh1, Hatice N Sen, Marcus Colyer, Michael Zapor, Keith Wroblewski.   

Abstract

PURPOSE OF REVIEW: Despite recent downtrends, tuberculosis remains a worldwide public health concern. This review provides an update on recent demographic data, clinical and experimental data, and diagnostic modalities. RECENT
FINDINGS: Quantitative PCR showing mycobacterial load in intraocular fluids may have an emerging role in the diagnosis of ocular tuberculosis when used in combination with ophthalmic features of tuberculosis. Recent investigations in porcine models of ocular tuberculosis have provided valuable insight into the microbiologic, histologic, and clinical features of Mycobacterium tuberculosis infection of the choroid. Differentiating features between sarcoidosis and tuberculosis include tuberculin skin test status, the presence of ocular surface disease, and the anatomic relationship between vasculitis and choroiditis.
SUMMARY: The diagnosis of presumed ocular tuberculosis remains a clinical challenge with currently available diagnostic modalities. Although newer interferon-γ release assays can distinguish exposure to M. tuberculosis from the Bacille-Calmette-Guérin vaccine strain, they currently lack the specificity to distinguish between latent tuberculosis infection and active tuberculosis. Continued improvement in the currently available molecular diagnostic techniques including quantitative PCR may be valuable in our ability to establish an earlier etiologic diagnosis and institute appropriate antimycobacterial therapy.

Entities:  

Mesh:

Year:  2012        PMID: 23047173     DOI: 10.1097/ICU.0b013e328358ba01

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  21 in total

1.  Ocular Tuberculosis.

Authors:  Julian A Marin-Acevedo; Razvan M Chirila; Jennifer B Cowart
Journal:  J Gen Intern Med       Date:  2019-07-24       Impact factor: 5.128

2.  Role of molecular diagnostics in ocular microbiology.

Authors:  Parisa Taravati; Deborah Lam; Russell N Van Gelder
Journal:  Curr Ophthalmol Rep       Date:  2013-12-01

Review 3.  Diagnostic vitrectomy for infectious uveitis.

Authors:  Abdallah Jeroudi; Steven Yeh
Journal:  Int Ophthalmol Clin       Date:  2014

4.  Ophthalmic Presentation of Disseminated Tuberculosis with Relapse-Immunological Profile.

Authors:  Bineeta Kashyap; Nisha Goyal; G K Das; N P Singh; I R Kaur
Journal:  Indian J Clin Biochem       Date:  2018-02-21

5.  Ocular Tuberculosis--A Clinical Conundrum.

Authors:  Cecilia Lee; Rupesh Agrawal; Carlos Pavesio
Journal:  Ocul Immunol Inflamm       Date:  2015-06-25       Impact factor: 3.070

6.  Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis.

Authors:  Sarah John; Oliver H Bell; Leslie Wilson; David A Copland; Kathryn L Pepple
Journal:  J Vis Exp       Date:  2021-12-17       Impact factor: 1.355

7.  Profile of serpiginous choroiditis in a tertiary eye care centre in eastern India.

Authors:  Kumar Saurabh; Pradeep Kumar Panigrahi; Amitabh Kumar; Rupak Roy; Jyotirmay Biswas
Journal:  Indian J Ophthalmol       Date:  2013-11       Impact factor: 1.848

8.  Transcriptional signatures of Mycobacterium tuberculosis in mouse model of intraocular tuberculosis.

Authors:  Sudhanshu Abhishek; Michelle Beth Ryndak; Alpa Choudhary; Sumedha Sharma; Amod Gupta; Vishali Gupta; Nirbhai Singh; Suman Laal; Indu Verma
Journal:  Pathog Dis       Date:  2019-07-01       Impact factor: 3.166

9.  Structural changes of the choroid in sarcoid- and tuberculosis-related granulomatous uveitis.

Authors:  H Mehta; D A Sim; P A Keane; J Zarranz-Ventura; K Gallagher; C A Egan; M Westcott; R W J Lee; A Tufail; C E Pavesio
Journal:  Eye (Lond)       Date:  2015-05-29       Impact factor: 3.775

10.  The Association between QuantiFERON-TB Gold Test and Clinical Manifestations of Uveitis in the United States.

Authors:  Mehmet Yakin; Natasha Kesav; Shuk Kei Cheng; Sonny Caplash; Sapna Gangaputra; H Nida Sen
Journal:  Am J Ophthalmol       Date:  2021-05-02       Impact factor: 5.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.